Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GMMG-CONCEPT: Isatuximab + carfilzomib + lenalidomide + dexamethasone in newly diagnosed high-risk multiple myeloma
2024-511791-32-00Phase 2Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Aug 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of isatuximab, carfilzomib, lenalidomide and dexamethasone in multiple myeloma (MM), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: MRD negativity after consolidation. Started Aug 2017; status: completed.
02
Drugs
isatuximabcarfilzomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-511791-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511791-32-00.